House Bill 1087

CODING: Words stricken are deletions; words underlined are additions.







    Florida House of Representatives - 2000                HB 1087

        By Representatives Pruitt and Sanderson






  1                      A bill to be entitled

  2         An act relating to delivery of health care

  3         services; creating a catastrophic

  4         pharmaceutical expense assistance program;

  5         providing eligibility; prescribing duties of

  6         the Agency for Health Care Administration and

  7         other entities; providing for rules; requiring

  8         a report; requiring pharmacies that participate

  9         in the program or in Medicaid to agree to

10         limitations on compensation; providing for

11         certain professional regulatory boards to adopt

12         rules to discourage their respective

13         practitioners from accepting certain types of

14         compensation from pharmaceutical manufacturers;

15         requiring disclosure of certain information

16         relating to such compensation; providing

17         legislative intent; providing appropriations;

18         providing an effective date.

19

20  Be It Enacted by the Legislature of the State of Florida:

21

22         Section 1.  Catastrophic pharmaceutical expense

23  assistance.--

24         (1)  PROGRAM ESTABLISHED.--There is established a

25  program to provide financial assistance to low-income elderly

26  individuals with catastrophic pharmaceutical expenses.

27         (2)  ELIGIBILITY.--Eligibility is limited to those

28  individuals who do not qualify for assistance under the

29  Medicaid program and who:

30         (a)  Are over the age of 65;

31

                                  1

CODING: Words stricken are deletions; words underlined are additions.






    Florida House of Representatives - 2000                HB 1087

    286-232-00






  1         (b)  Have an income at or below 250 percent of the

  2  federal poverty level; and

  3         (c)  Have out-of-pocket prescription expenses that

  4  exceed or are projected to exceed 10 percent of their annual

  5  income, after payments by other liable entities are deducted.

  6         (3)  BENEFITS.--Medications covered under the

  7  catastrophic pharmaceutical expense assistance program are

  8  those covered under the Medicaid program in section

  9  409.906(20), Florida Statutes. Payments shall be for the total

10  amount of prescription drug expenses above 10 percent of an

11  individual's annual income.

12         (4)  ADMINISTRATION.--The catastrophic pharmaceutical

13  expense assistance program shall be administered by the Agency

14  for Health Care Administration, in consultation with the

15  Department of Elderly Affairs. To the extent possible,

16  administration of the program, including eligibility

17  determination, claims processing, and reporting, shall use

18  existing administrative mechanisms, including the Medicaid

19  fiscal agent system and area agencies on aging.

20         (a)  The Agency for Health Care Administration shall

21  make payments for prescription drugs on behalf of eligible

22  individuals.

23         (b)  The Agency for Health Care Administration and the

24  Department of Elderly Affairs shall develop a single-page

25  application for the catastrophic pharmaceutical expense

26  assistance program.

27         (c)  The Agency for Health Care Administration shall,

28  by rule, establish eligibility requirements, limits on

29  participation, benefit limitations, a requirement for generic

30  drug substitution, and other program parameters comparable to

31

                                  2

CODING: Words stricken are deletions; words underlined are additions.






    Florida House of Representatives - 2000                HB 1087

    286-232-00






  1  those of the Medicaid program for the catastrophic

  2  pharmaceutical expense assistance program.

  3         (d)  By January 1 of each year, the Agency for Health

  4  Care Administration shall report to the Legislature on the

  5  operation of the program. The report shall include information

  6  on the number of individuals served, use rates, and

  7  expenditures under the program. The report shall also address

  8  the impact of the program on reducing unmet pharmaceutical

  9  drug needs among the elderly and recommend programmatic

10  changes.

11         (5)  NONENTITLEMENT.--The catastrophic pharmaceutical

12  expense assistance program is not an entitlement and shall be

13  the payor of last resort.

14         Section 2.  Medicare prescription discount program.--As

15  a condition of participation in the Florida Medicaid program

16  or the catastrophic pharmaceutical expense assistance program,

17  a pharmacy must agree that the charge to any Medicare

18  beneficiary showing a Medicare card when presenting a

19  prescription shall be no greater than the amount paid to that

20  pharmacy for ingredients and dispensing under the Florida

21  Medicaid program, plus 2.5 percent of the Medicaid payment for

22  the ingredients of the prescription.

23         Section 3.  The Legislature recognizes that the state

24  has a compelling interest in maintaining the integrity of

25  health care professions. The Legislature finds that physicians

26  and other health care practitioners have a fiduciary

27  responsibility to act in the best interests of their patients,

28  who place their trust in, and are dependent on, the

29  professional expertise of health care practitioners when

30  seeking their services. The Legislature finds that the nature

31  of the relationship between the patient and the health care

                                  3

CODING: Words stricken are deletions; words underlined are additions.






    Florida House of Representatives - 2000                HB 1087

    286-232-00






  1  practitioner and the underlying trust in that relationship

  2  prompt the need for guidelines to avoid the receipt by health

  3  care practitioners of gifts, payments, subsidies, or other

  4  financial inducements from pharmaceutical manufacturers which

  5  adversely shape the health care practitioners' independent

  6  professional judgment and which undermine their patients'

  7  access to treatment, course of care, and clinical outcomes.

  8         (1)  The Board of Medicine, the Board of Osteopathic

  9  Medicine, the Board of Podiatric Medicine, and the Board of

10  Dentistry shall adopt, by rule, guidelines to discourage

11  health care practitioners under their respective jurisdictions

12  from accepting gifts, payments, subsidies, or other financial

13  inducements from pharmaceutical manufacturers which may

14  undermine the practitioners' independent professional

15  judgment. Any gift, payment, or other financial inducement

16  that a health care practitioner receives from a pharmaceutical

17  manufacturer should primarily entail a benefit to his or her

18  patients and should not be of substantial value. For purposes

19  of this section, a gift, payment, subsidy, or other financial

20  inducement does not include complimentary samples of medicinal

21  drugs.

22         (2)  To ensure that patients are adequately informed

23  about their care and to assist the health care practitioner in

24  avoiding the receipt of gifts, payments, subsidies, or other

25  financial inducements from pharmaceutical manufacturers which

26  may not be justified, the Board of Medicine, the Board of

27  Osteopathic Medicine, the Board of Podiatric Medicine, and the

28  Board of Dentistry each shall require each health care

29  practitioner under its regulatory jurisdiction to disclose to

30  the Department of Health, as a condition of license renewal,

31  the receipt of gifts, payments, subsidies, or other financial

                                  4

CODING: Words stricken are deletions; words underlined are additions.






    Florida House of Representatives - 2000                HB 1087

    286-232-00






  1  inducements from pharmaceutical manufacturers which conflict

  2  with that health care practitioner's duty of loyalty to his or

  3  her patients.

  4         Section 4.  There is appropriated to the Agency for

  5  Health Care Administration the sum of $15,244,200 from the

  6  Medical Care Trust Fund and the sum of $11,755,800 from the

  7  General Revenue Fund to provide Medicaid for services for

  8  persons who are eligible under section 409.904(1), Florida

  9  Statutes, and whose incomes are greater than 90 percent of the

10  federal poverty level but no greater than 100 percent of the

11  federal poverty level.

12         Section 5.  There is appropriated the sum of $42

13  million from the General Revenue Fund to the Agency for Health

14  Care Administration for the purpose of implementing section 1

15  relating to the catastrophic pharmaceutical expense assistance

16  program.

17         Section 6.  There is appropriated the sum of $1 million

18  from the General Revenue Fund to the Agency for Health Care

19  Administration to develop a computerized system that allows

20  participating pharmacies to determine allowable maximum

21  payments for prescription drugs under section 2.

22         Section 7.  This act shall take effect upon becoming a

23  law.

24

25

26

27

28

29

30

31

                                  5

CODING: Words stricken are deletions; words underlined are additions.






    Florida House of Representatives - 2000                HB 1087

    286-232-00






  1            *****************************************

  2                       LEGISLATIVE SUMMARY

  3    Creates a catastrophic pharmaceutical expense assistance
      program to assist elderly persons meeting established
  4    criteria in paying for prescription drugs. Requires
      pharmacies participating in the program or in Medicaid to
  5    limit their compensation for drugs. Requires the Board of
      Medicine, the Board of Osteopathic Medicine, the Board of
  6    Podiatric Medicine, and the Board of Dentistry to adopt
      rules to discourage the professionals under their
  7    jurisdictions from accepting compensation from
      pharmaceutical manufacturers which would undermine
  8    independent professional judgment. Requires professionals
      receiving such compensation to report the compensation
  9    annually to the Department of Health.

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

                                  6